van Raalte DH - Search Results

1

Sodium glucose cotransporter 2 inhibition and renal ischemia: implications for future clinical trials.

van Raalte DH, Cherney DZI. van Raalte DH, et al. Kidney Int. 2018 Sep;94(3):459-462. doi: 10.1016/j.kint.2018.05.026. Kidney Int. 2018. PMID: 30143067 Free article.

2

ACE-I vs. ARB for blood pressure control in diabetic kidney disease.

Tonneijck L, Muskiet MH, van Raalte DH. Tonneijck L, et al. Among authors: van raalte dh. Kidney Int. 2014 Dec;86(6):1270. doi: 10.1038/ki.2014.262. Kidney Int. 2014. PMID: 25427090 Free article. No abstract available.

3

Incretin-based drugs and renoprotection-is hyperfiltration key?

Tonneijck L, Smits MM, van Raalte DH, Muskiet MH. Tonneijck L, et al. Among authors: van raalte dh. Kidney Int. 2015 Mar;87(3):660-1. doi: 10.1038/ki.2014.398. Kidney Int. 2015. PMID: 25723636 Free article. No abstract available.

4

SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.

van Bommel EJM, Muskiet MHA, Tonneijck L, Kramer MHH, Nieuwdorp M, van Raalte DH. van Bommel EJM, et al. Among authors: van raalte dh. Clin J Am Soc Nephrol. 2017 Apr 3;12(4):700-710. doi: 10.2215/CJN.06080616. Epub 2017 Mar 2. Clin J Am Soc Nephrol. 2017. PMID: 28254770 Free PMC article. Review.

5

SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management.

van Baar MJB, van Ruiten CC, Muskiet MHA, van Bloemendaal L, IJzerman RG, van Raalte DH. van Baar MJB, et al. Among authors: van ruiten cc, van raalte dh, van bloemendaal l. Diabetes Care. 2018 Aug;41(8):1543-1556. doi: 10.2337/dc18-0588. Diabetes Care. 2018. PMID: 30030256 Review.

6

Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus.

Tonneijck L, Muskiet MHA, Blijdorp CJ, Smits MM, Twisk JW, Kramer MHH, Danser AHJ, Diamant M, Joles JA, Hoorn EJ, van Raalte DH. Tonneijck L, et al. Among authors: van raalte dh. Am J Physiol Renal Physiol. 2019 Feb 1;316(2):F231-F240. doi: 10.1152/ajprenal.00432.2018. Epub 2018 Oct 24. Am J Physiol Renal Physiol. 2019. PMID: 30353743 Free article. Clinical Trial.

7

Mineralocorticoid Antagonism and Diabetic Kidney Disease.

Lytvyn Y, Godoy LC, Scholtes RA, van Raalte DH, Cherney DZ. Lytvyn Y, et al. Among authors: van raalte dh. Curr Diab Rep. 2019 Jan 23;19(1):4. doi: 10.1007/s11892-019-1123-8. Curr Diab Rep. 2019. PMID: 30673886 Review.

8

Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?

Scholtes RA, van Baar MJB, Lytvyn Y, Bjornstad P, Nieuwdorp M, Cherney DZI, van Raalte DH. Scholtes RA, et al. Among authors: van baar mjb, van raalte dh. Diabetes Obes Metab. 2019 Apr;21 Suppl 2(Suppl 2):24-33. doi: 10.1111/dom.13692. Diabetes Obes Metab. 2019. PMID: 30843294 Free PMC article. Review.

9

Renal hyperfiltration defined by high estimated glomerular filtration rate: A risk factor for cardiovascular disease and mortality.

Kanbay M, Ertuglu LA, Afsar B, Ozdogan E, Kucuksumer ZS, Ortiz A, Covic A, Kuwabara M, Cherney DZI, van Raalte DH, de Zeeuw D. Kanbay M, et al. Among authors: van raalte dh. Diabetes Obes Metab. 2019 Nov;21(11):2368-2383. doi: 10.1111/dom.13831. Epub 2019 Jul 29. Diabetes Obes Metab. 2019. PMID: 31297976

10

SGLT2 inhibitors' interaction with other renoactive drugs in type 2 diabetes patients: still a lot to learn.

van Baar MJB, Scholtes RA, van Raalte DH. van Baar MJB, et al. Among authors: van raalte dh. Kidney Int. 2019 Aug;96(2):283-286. doi: 10.1016/j.kint.2019.03.032. Kidney Int. 2019. PMID: 31331468 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

232 results

Search Page

Filters